Engineered microorganisms for detection of diseased cells
US-2024118283-A1 · Apr 11, 2024 · US
Humanized transgenic mouse model
US9557323B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9557323-B2 |
| Application number | US-201113581483-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 26, 2011 |
| Priority date | Sep 24, 2010 |
| Publication date | Jan 31, 2017 |
| Grant date | Jan 31, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided is a transgenic animal model for testing immunogenicity and protective efficacy of human vaccines and the method for generating such a multitransgenic animal. Also disclosed are methods for screening compositions for human vaccine development. More specifically, a mouse model capable of expressing human leukocyte antigen DR4, and human costimulatory molecules (CD80) upon infusion of human HLA-matched hematopoietic stem cells, which can develop into a functional human immune system is provided.
First claim
Opening claim text (preview).
What is claimed is: 1. A transgenic NOD mouse whose genome comprises a nucleic acid construct comprising a nucleic acid encoding human leukocyte antigen DR4 (HLA-DR4) operably linked to mouse I-E d promoter, wherein the transgenic NOD mouse is homozygous for a null mutation in the RAG-1(Rag1 −/− ) gene and null for the mouse interleukin 2 receptor gamma chain (IL-2Rγc) gene; and wherein the transgenic mouse expresses said HLA-DR4 and develops a functional human immune system comprising human T-cells, human B-cells and serum levels of human IgA, IgM, IgE and IgG, wherein said functional human immune system in said mouse is produced by infusion of human HLA-matched hematopoietic stem cells. 2. The transgenic mouse of claim 1 , wherein genome of said transgenic mouse further comprising an expression vector comprising nucleic acid encoding human costimulatory molecules (CD80) operably linked to a rat insulin promoter (RIP).
Assignees
Inventors
Classifications
inducing gain of function · CPC title
Murine · CPC title
Animal model, e.g. for test or diseases · CPC title
- G01N33/5088Primary
of vertebrates · CPC title
- A01K67/0278Primary
Knock-in vertebrates, e.g. humanised vertebrates · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9557323B2 cover?
- Provided is a transgenic animal model for testing immunogenicity and protective efficacy of human vaccines and the method for generating such a multitransgenic animal. Also disclosed are methods for screening compositions for human vaccine development. More specifically, a mouse model capable of expressing human leukocyte antigen DR4, and human costimulatory molecules (CD80) upon infusion of hu…
- Who is the assignee on this patent?
- Casares Sofia A, Brumeanu Teodor D, Richie Thomas L, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification G01N33/5088. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Jan 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).